Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Paul Hud­son: Sanofi 'least ex­posed' to gener­ic com­pe­ti­tion as Big Phar­ma dou­bles down on Dupix­ent

As Sanofi gears to change strate­gies to in­crease Dupix­ent sales and add in­di­ca­tions amid a sprawl­ing R&D trim, CEO Paul Hud­son gave some in­sight in­to how it plans to move for­ward.

The plan is two-prong: Hud­son told in­vestors and an­a­lysts on the phar­ma’s Q2 earn­ings call that it’s the “least ex­posed” Big Phar­ma to the threat of gener­ic com­pe­ti­tion through the rest of the 2020s, while its Re­gen­eron-part­nered Dupix­ent will be­come an even more im­por­tant tool in Sanofi’s reper­toire.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.